Free Trial
→ IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead? (From American Alternative) (Ad)tc pixel

International Biotechnology (LON:IBT) Shares Cross Above 200 Day Moving Average - Time to Sell?

Written by MarketBeat
September 11, 2025
International Biotechnology logo with Financial Services background

Key Points

  • International Biotechnology shares crossed above their 200-day moving average, indicating a potential bullish trend.
  • The stock last traded at GBX 708 ($9.61) after reaching a high of GBX 715.93 ($9.72) during the session.
  • The company aims for long-term capital growth by investing in biotechnology and life sciences firms with promising growth prospects.
  • Five stocks to consider instead of International Biotechnology.

Shares of International Biotechnology (LON:IBT - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 616.57 ($8.37) and traded as high as GBX 715.93 ($9.72). International Biotechnology shares last traded at GBX 708 ($9.61), with a volume of 87,239 shares.

International Biotechnology Trading Down 1.1%

The business has a 50 day moving average of GBX 656.29 and a 200-day moving average of GBX 617.63. The stock has a market cap of £233.89 million, a PE ratio of 1,435.66 and a beta of 0.21.

About International Biotechnology

(Get Free Report)

The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.

Recommended Stories

Should You Invest $1,000 in International Biotechnology Right Now?

Before you consider International Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list.

While International Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover
10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.